| Salwan L Toma, MD | |
|
16001 W 9 Mile Rd, Southfield, MI 48075-4818 | |
| (248) 849-3971 | |
| Not Available |
| Full Name | Salwan L Toma |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 30 Years |
| Location | 16001 W 9 Mile Rd, Southfield, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548279763 | NPI | - | NPPES |
| 4736888 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301074502 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Providence Hospital, Southfield And Novi | Southfield, MI | Hospital |
| Ascension St John Hospital | Detroit, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Art Of Radiology Imaging Associates, Pllc | 1951795319 | 47 |
| Basha Diagnostics P C | 5890681746 | 34 |
| Southfield Radiology Associates, Pllc | 6800877481 | 29 |
| Vmd Primary Providers Eastern Michigan Pc | 9234480575 | 59 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
| Entity Name | Basha Diagnostics P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770693798 PECOS PAC ID: 5890681746 Enrollment ID: O20040226000460 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
| Entity Name | Southfield Radiology Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831103670 PECOS PAC ID: 6800877481 Enrollment ID: O20040528000549 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
| Entity Name | Envision Diagnostic Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144543562 PECOS PAC ID: 9335264472 Enrollment ID: O20100914000252 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
| Entity Name | Vmd Primary Providers Eastern Michigan Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336625540 PECOS PAC ID: 9234480575 Enrollment ID: O20180925002900 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
| Entity Name | Ascension Medical Group Genesys |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598248718 PECOS PAC ID: 7214288281 Enrollment ID: O20181002000367 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
| Entity Name | Art Of Radiology Imaging Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003571076 PECOS PAC ID: 1951795319 Enrollment ID: O20220301000129 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Salwan L Toma, MD 26850 Providence Pkwy Ste 140, Novi, MI 48374-1253 Ph: (248) 308-2745 | Salwan L Toma, MD 16001 W 9 Mile Rd, Southfield, MI 48075-4818 Ph: (248) 849-3971 |
News Archive
Kaiser Health News staff writer Jenny Gold writes about a COBRA extension moving through Congress. "A proposal to extend the health insurance subsidies for Americans who have lost jobs as a result of the recession is one step closer to gaining congressional approval.
One of the emerging questions about the coronavirus that scientists are working to understand is why developing countries are showing markedly lower rates of mortality in COVID-19 cases than expected.
Transgenomic, Inc. today announced that Jeana DaRe, Ph.D., Assistant CLIA Laboratory Director at Transgenomic, presented clinical findings from patients tested for nuclear mitochondrial disorders using Transgenomic's NuclearMitome Test on Thursday, March 29, at the 2012 Annual Meeting of the American College of Medical Genetics (ACMG) in Charlotte, North Carolina.
The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").
› Verified 8 days ago
Anicia Mirchandani, Radiology Medicare: Medicare Enrolled Practice Location: 22250 Providence Dr, Southfield, MI 48075 Phone: 248-849-3281 | |
Carole Roseland, DO Radiology Medicare: Accepting Medicare Assignments Practice Location: 24500 Northwestern Hwy, Southfield, MI 48075 Phone: 248-353-1280 Fax: 248-353-6193 | |
Kyle Warwick Eaton, MD Radiology Medicare: Medicare Enrolled Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-2203 Fax: 248-849-5395 | |
Dr. Matthew Howard Greenspan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Maria Crumes, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 24681 Northwestern Hwy, Southfield, MI 48075 Phone: 248-352-2000 Fax: 248-324-1477 | |
Jessica Marie Kaniowski, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Dr. Rani Bashiti, Radiology Medicare: Accepting Medicare Assignments Practice Location: 16001 W. 9 Mild Rd,, Southfield, MI 48075 Phone: 248-849-3000 |